Average Annual Growth of About 13% Over 5 Years, Entering the "Blockbuster Product" Segment

Yuhan Corporation announced on the 6th that annual outpatient prescriptions for its dyslipidemia treatment Rosubamibeu have exceeded 100 billion won.

Rosubamibeu product image. Yuhan Corporation

Rosubamibeu product image. Yuhan Corporation

View original image

According to data from the pharmaceutical research agency Ubist, Rosubamibeu recorded 102.2 billion won in outpatient prescriptions in 2025. Now entering its 10th year since its 2016 launch, it has grown by an average of about 13% annually over the past five years and has joined the ranks of "blockbuster products" in the domestic hyperlipidemia treatment market.


Rosubamibeu is a combination drug that contains rosuvastatin and ezetimibe. It is available in four dosage strengths - 10/2.5 mg, 10/5 mg, 10/10 mg, and 10/20 mg - allowing stepwise prescribing tailored to the patient's condition.


In clinical studies involving patients aged 70 years or older with atherosclerotic cardiovascular disease, Rosubamibeu showed a significantly lower risk of statin-associated muscle adverse reactions and new-onset diabetes compared with high-intensity rosuvastatin monotherapy. The LDL cholesterol-lowering effect was maintained at a similar level.



Since its launch, Rosubamibeu has continuously accumulated evidence from clinical trials and real-world practice in Korean patients. The annual number of prescriptions has exceeded 1 million. Yuhan Corporation plans to continue follow-up research focusing on helping elderly patients achieve their lipid targets.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing